Summary
Walmart Inc. (WMT) filed an 8-K on February 4, 2021, to disclose a statement regarding the dismissal of its lawsuit against the U.S. Department of Justice and the U.S. Drug Enforcement Agency (DEA). The lawsuit, filed in October 2020, concerned the roles and responsibilities of pharmacists and pharmacies under the Controlled Substances Act. The company has furnished a statement as an exhibit to this report, detailing this development.
Key Highlights
- 1Walmart is announcing the dismissal of its lawsuit against the U.S. Department of Justice and DEA.
- 2The lawsuit, initiated on October 22, 2020, focused on the Controlled Substances Act and the responsibilities of pharmacists and pharmacies.
- 3The company has provided a formal statement regarding this dismissal, included as an exhibit to the 8-K filing.
- 4This filing is made under Regulation FD Disclosure, indicating it's for public information dissemination.
- 5The information furnished is not deemed 'filed' for the purposes of Section 18 of the Exchange Act, limiting liability.
Frequently Asked Questions
The main purpose of this 8-K filing is to inform investors and the public that Walmart has dismissed its lawsuit against the U.S. Department of Justice and the U.S. Drug Enforcement Agency.
The lawsuit, filed in October 2020, was related to the roles and responsibilities of pharmacists and pharmacies concerning the Controlled Substances Act.
No, this filing primarily concerns a legal matter and the dismissal of a lawsuit. It does not present new financial statements or results, but rather a statement regarding the legal proceedings.
More details can be found in Exhibit 99.1, which is a statement by Walmart Inc. furnished with this 8-K filing, explaining the dismissal of the lawsuit.